The Alliance Foundation Trials, LLC (AFT), in conjunction with Pfizer and six international cancer research groups, have announced the launch of PATINA - a randomized, open-label, Phase 3 clinical study of the cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor palbociclib (also known as IBRANCE®).

Two of the nation's leading health organizations, health and well-being company Humana Inc. (NYSE: HUM) and biotechnology company Amgen (NASDAQ:AMGN), have teamed up to identify opportunities to improve health outcomes and improve efficiency by unlocking new insights from the real world health care experiences of Humana's 13 million members.

Novartis and Medicines for Malaria Venture (MMV) have launched a patient trial for KAF156, a next-generation antimalarial compound with the potential to treat drug-resistant strains of the malaria parasite. The trial will test the efficacy of KAF156 in combination with a new, improved formulation of the existing antimalarial lumefantrine.

The Lyfebulb-Novo Nordisk Innovation Summit 2017 will recognize and empower international Patient Entrepreneurs with big ideas that disrupt the future of diabetes management. Patient Entrepreneurs have a unique ability to create value-adding disease management solutions beyond therapy. The aim is to support patient-driven innovation and laser-focus on improving the quality of life for those living with diabetes.

Amgen (NASDAQ:AMGN) today announced that the New England Journal of Medicine (NEJM) published results from the Repatha® (evolocumab) cognitive function trial (EBBINGHAUS), which was conducted in a subset of patients enrolled in the randomized, placebo-controlled Repatha cardiovascular outcomes study (FOURIER).

Bristol-Myers Squibb Company (NYSE: BMY) announced topline results today from the CheckMate -214 trial investigating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) versus sunitinib in intermediate and poor-risk patients previously untreated advanced or metastatic renal cell carcinoma.

Boehringer Ingelheim has delivered positive results for the first half of 2017. Net sales increased by 24 per cent on the same period in the previous year to 9.2 billion euros after adjustment for currency effects (+27 per cent in euro terms).(1) In the first half of the year, Boehringer Ingelheim's figures for the first time included the net sales of Sanofi’s animal health business, Merial, which was acquired at the start of the year.